Neumora: Koastal-1 Readout For MDD Treatment Is First Study On Deck
Portfolio Pulse from
Neumora Therapeutics is preparing to release phase 3 KOASTAL-1 study data for Navacaprant in treating MDD by the end of 2024. The company has sufficient cash to fund operations until mid-2026, reducing near-term dilution risk.
December 24, 2024 | 6:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neumora Therapeutics is set to release phase 3 data for Navacaprant in MDD treatment by end of 2024. The company has $341.3M in cash, funding operations until mid-2026, reducing dilution risk.
The upcoming phase 3 data release for Navacaprant in MDD treatment is a significant milestone for Neumora, potentially boosting investor confidence. The company's strong cash position reduces the risk of near-term dilution, which is positive for stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100